Research programme: anti TIGIT antibodies - Cascadian Therapeutics

Drug Profile

Research programme: anti TIGIT antibodies - Cascadian Therapeutics

Alternative Names: TIGIT antibodies - Cascadian

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cascadian Therapeutics
  • Class Antibodies; Antineoplastics; Immunotherapies
  • Mechanism of Action CD8 positive T lymphocyte modulators; Checkpoint kinase inhibitors; Immunostimulants; Natural killer cell modulators; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Mar 2018 Cascadian Therapeutics has been acquired by Seattle Genetics
  • 04 Jan 2018 The anti TIGIT antibodies programme is available for licensing as of 04 Jan 2018. http://www.cascadianrx.com/
  • 07 Apr 2017 Pharmacodynamic results from a preclinical trial in Cancer reported at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top